PubMed for id: 435

Year	Number of Results
1978	1
1981	1
1986	1
1988	2
1989	1
1990	1
1991	2
1992	1
1993	2
1997	2
2001	2
2002	4
2003	1
2004	1
2005	1
2007	1
2008	1
2009	2
2010	3
2011	6
2012	3
2013	3
2014	4
2015	3
2016	3
2017	5
2019	4
2020	3
2021	3
2022	3
2023	3
2024	1

1

Biomarkers for liver disease in urea cycle disorders.

Nagamani SCS, Ali S, Izem R, Schady D, Masand P, Shneider BL, Leung DH, Burrage LC. Nagamani SCS, et al. Mol Genet Metab. 2021 Jun;133(2):148-156. doi: 10.1016/j.ymgme.2021.04.001. Epub 2021 Apr 8. Mol Genet Metab. 2021. PMID: 33846069 Free PMC article. Clinical Trial.

2

From genotype to phenotype: Early prediction of disease severity in argininosuccinic aciduria.

Zielonka M, Garbade SF, Gleich F, Okun JG, Nagamani SCS, Gropman AL, Hoffmann GF, Kölker S, Posset R; Urea Cycle Disorders Consortium (UCDC) and the European registry and network for Intoxication type Metabolic Diseases (E-IMD) Consortia Study Group. Zielonka M, et al. Hum Mutat. 2020 May;41(5):946-960. doi: 10.1002/humu.23983. Epub 2020 Jan 30. Hum Mutat. 2020. PMID: 31943503 Free PMC article.

3

Whole-Exome Sequencing Identified a Novel Compound Heterozygous Genotype in ASL in a Chinese Han Patient with Argininosuccinate Lyase Deficiency.

Zhao M, Hou L, Teng H, Li J, Wang J, Zhang K, Yang L. Zhao M, et al. Biomed Res Int. 2019 Apr 30;2019:3530198. doi: 10.1155/2019/3530198. eCollection 2019. Biomed Res Int. 2019. PMID: 31183366 Free PMC article.

4

Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells.

Hung YH, Huang HL, Chen WC, Yen MC, Cho CY, Weng TY, Wang CY, Chen YL, Chen LT, Lai MD. Hung YH, et al. Oncol Rep. 2017 Feb;37(2):969-978. doi: 10.3892/or.2016.5334. Epub 2016 Dec 23. Oncol Rep. 2017. PMID: 28035420 Free PMC article.

5

Silencing of argininosuccinate lyase inhibits colorectal cancer formation.

Huang HL, Chen WC, Hsu HP, Cho CY, Hung YH, Wang CY, Lai MD. Huang HL, et al. Oncol Rep. 2017 Jan;37(1):163-170. doi: 10.3892/or.2016.5221. Epub 2016 Nov 7. Oncol Rep. 2017. PMID: 27840980

6

Argininosuccinate lyase is a potential therapeutic target in breast cancer.

Huang HL, Chen WC, Hsu HP, Cho CY, Hung YH, Wang CY, Lai MD. Huang HL, et al. Oncol Rep. 2015 Dec;34(6):3131-9. doi: 10.3892/or.2015.4280. Epub 2015 Sep 16. Oncol Rep. 2015. PMID: 26397737

7

Unstable argininosuccinate lyase in variant forms of the urea cycle disorder argininosuccinic aciduria.

Hu L, Pandey AV, Balmer C, Eggimann S, Rüfenacht V, Nuoffer JM, Häberle J. Hu L, et al. J Inherit Metab Dis. 2015 Sep;38(5):815-27. doi: 10.1007/s10545-014-9807-3. Epub 2015 Mar 17. J Inherit Metab Dis. 2015. PMID: 25778938 Free article.

8

Mutations and polymorphisms in the human argininosuccinate lyase (ASL) gene.

Balmer C, Pandey AV, Rüfenacht V, Nuoffer JM, Fang P, Wong LJ, Häberle J. Balmer C, et al. Hum Mutat. 2014 Jan;35(1):27-35. doi: 10.1002/humu.22469. Epub 2013 Nov 25. Hum Mutat. 2014. PMID: 24166829

9

Understanding the role of argininosuccinate lyase transcript variants in the clinical and biochemical variability of the urea cycle disorder argininosuccinic aciduria.

Hu L, Pandey AV, Eggimann S, Rüfenacht V, Möslinger D, Nuoffer JM, Häberle J. Hu L, et al. J Biol Chem. 2013 Nov 29;288(48):34599-611. doi: 10.1074/jbc.M113.503128. Epub 2013 Oct 17. J Biol Chem. 2013. PMID: 24136197 Free PMC article.

10

Reduced expression of argininosuccinate lyase is closely associated with postresectional survival in hepatocellular carcinoma: an immunohistochemistry study of 61 cases.

Yang H, Zhai G, Ji X, Su J, Lin M. Yang H, et al. Appl Immunohistochem Mol Morphol. 2012 Dec;20(6):602-6. doi: 10.1097/PAI.0b013e318250c814. Appl Immunohistochem Mol Morphol. 2012. PMID: 22531684

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

62 results

Results by year